We last covered HelloBetter last year, when the company known for its various digital therapeutics products, launched its German, DiGa-listed vaginismus program in the US. HelloGina, as the program is called, combines interactive content, science-backed techniques goal setting, and personal support via in-app coaches.
A few months later the HelloBetter has now raised a €7M in Series A+ funding led by MassMutual Ventures to support further commercialization in Europe and the US. Other participants in the round include HealthCap, Sparrow Ventures, Hevella Capital, and Expon Capital.
The company also announced FDA breakthrough device designation for its online therapy program to help those experiencing panic attacks. The company now has five years to submit all relevant data required for FDA approval, after which the program can be prescribed in the US.
